Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Phio Pharmaceuticals Corp
PHIO
Healthcare
Biotechnology
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or...
drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PHIO)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
Next
(92)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 22, 2024 2:45pm
Why Is Penny Stock Phio Pharmaceuticals Trading Higher On Mo
BREAKING NEWS: $PHIO Why Is Penny Stock Phio Pharmaceuticals Trading Higher On Monday? | BenzingaPhio Pharmaceuticals Corp@(NASDAQ:PHIO) shares are trading higher after the company announced it is
...more
(92)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 22, 2024 1:45pm
Intratumoral Injection of Phio's PH-762 significantly inhibi
Breaking News: $PHIO Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells | Benzinga-Injection in murine
...more
(92)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jan 31, 2024 10:45am
Phio Pharmaceuticals Announces Data Showing INTASYL May Resu
NEWS: $PHIO Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies-- New preclinical data to be presented at Immunotherapy
...more
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Dec 07, 2023 8:44am
Phio ...warrants are exercised....dilution
Cha ching!!!!!!!!!
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Dec 06, 2023 10:57am
PHIO.....kaboom
Lets go
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 09, 2023 4:30pm
New Press Release - Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 09, 2023 7:30am
New Press Release - Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that the first...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 03, 2023 12:00pm
New Press Release - Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control
Intratumoral injection of INTASYL self-delivering RNAi compound targeting CTLA-4 (27790) in combination with systemic anti-PD-1 antibody therapy offers a novel approach to combination Immune Checkpoint Inhibition (ICI) therapies MARLBOROUGH, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Phio...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 12, 2023 11:00am
New Press Release - Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
MARLBOROUGH, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that new preclinical...
read article.
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 11, 2023 3:45pm
PHIO.....ten to one this will be huge in AH
I just had to sell and crystalize my profit Cheers to all !!!!!
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 11, 2023 3:42pm
PHIO ....rock and roll hootchie cooo
Bi g bounce
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 11, 2023 2:28pm
PHIO.....and of course Mr. maggot does
the only thing he's good at....PB mode
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 11, 2023 2:24pm
PHIO....this should be gapping up
JMHO
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 11, 2023 2:22pm
phio....NOW FOR THE LAST HURDLE TO BUST
$2.35
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 11, 2023 1:57pm
PHIO...here we go Packers ...here we go ; )
Maybe
Prev
1
2
3
4
5
6
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Silvercorp to Acquire Adventus for Implied Consideration of C$0.50 per Share
Meet one of the Strongest Contenders to Lead Canada’s Cannabis Market
Multiple High-Grade Gold Hits at the Tonopah Gold Project Including 90 Meters at 2.0 gpt Gold
A Leading Provider in Virtual Healthcare Adds 4th Provincial Health Authority Contract
NOI Filed for Drill Program at Lithium/Uranium Project in Nevada